Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gains from Investment Securities: 2020-2025

Historic Gains from Investment Securities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $3.4 million.

  • Insight Molecular Diagnostics' Gains from Investment Securities fell 52.69% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 million, marking a year-over-year decrease of 132.20%. This contributed to the annual value of -$4.3 million for FY2024, which is 25.81% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Gains from Investment Securities of $3.4 million as of Q3 2025, which was up 20.47% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Gains from Investment Securities registered a high of $11.2 million during Q4 2023, and its lowest value of -$18.3 million during Q1 2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was $1.8 million (2023), whereas its average is -$270,545.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 6,135.29% in 2021, then slumped by 21,296.67% in 2022.
  • Insight Molecular Diagnostics' Gains from Investment Securities (Quarterly) stood at $5.6 million in 2021, then crashed by 346.87% to -$13.9 million in 2022, then spiked by 180.69% to $11.2 million in 2023, then plummeted by 222.45% to -$13.7 million in 2024, then slumped by 52.69% to $3.4 million in 2025.
  • Its Gains from Investment Securities stands at $3.4 million for Q3 2025, versus $2.8 million for Q2 2025 and $879,000 for Q1 2025.